Interferon-beta increases the sensitivity of endometrial cancer cells to cell-mediated cytotoxicity.
Established monolayer cell lines derived from human endometrial carcinoma (Ishikawa and HEC-50) were sensitive to the cytotoxic activity of peripheral blood lymphocytes (PBLs). The percentages of hormone-responsive Ishikawa cells lysed by the cytotoxic activity of lymphocytes were 45.7 +/- 4.3 (mean +/- SE), 31.5 +/- 4.1, and 20.1 +/- 1.6, at effector/target (E/T) ratios of 50:1, 25:1, and 12:1, respectively. Values of 44.7 +/- 5.4%, 29.4 +/- 4.6%, and 20 +/- 4.9% were obtained when non-hormone-responsive HEC-50 cells were used as targets at the same E/T ratio. The percentages of epithelial and stromal cells, isolated from human endometrial cancer, lysed by the cytotoxic activity of lymphocytes were 40 +/- 5.4 and 25.2 +/- 3.8, respectively, at an E/T ratio of 25:1. The addition of interferon-beta (IFN-beta) to the culture increased tumor target cell sensitivity to the lytic activity of untreated PBL. The increase produced by 10 IU/ml of IFN-beta ranged between 0.60- and 0.89-fold (P < 0.01 Student's t test, two-tailed, unpaired) in Ishikawa cells and between 0.37- and 0.72-fold P < 0.05) in HEC-50 cells. Higher concentrations of IFN-beta (100 and 1000 IU/ml) were less effective in increasing the sensitivity of the target cells. There was no significant increase in the cytotoxic activity of lymphocytes treated with IFN-beta whereas cytotoxic activity toward untreated tumor target cells increased when lymphocytes were treated with IFN-alpha. The effects of IFN-beta were also evaluated using epithelial and stromal cells derived from human endometrial cancer. It was found that IFN-beta at low concentrations (10 IU/ml) significantly increased the sensitivity of both epithelial and stromal cells, by 48 and 73%, respectively. Our data indicate that Ishikawa, HEC-50, epithelial, and stromal cells may provide a useful experimental model for studying the effects of immunomodulant agents such as IFN-beta in hormone-related tumors. IFN-beta increases endometrial target cell sensitivity, rather than the lytic activity of lymphocytes.
Rossiello
F
F
Department of Obstetrics & Gynaecology, Universitá Cattolica del S. Cuore, Rome, Italy.
De Cicco Nardone
F
F
Dell'Acqua
S
S
D000230:Adenocarcinoma / Q000473:pathology*; D002450:Cell Communication / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D016889:Endometrial Neoplasms / Q000473:pathology*; D005260:Female; D006801:Humans; D016898:Interferon-alpha / Q000494:pharmacology; D016899:Interferon-beta / Q000494:pharmacology*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000473:pathology; D008213:Lymphocyte Activation; D008297:Male; D013602:T-Lymphocytes, Cytotoxic / Q000473:pathology*; D014407:Tumor Cells, Cultured
D016898:Interferon-alpha; D016899:Interferon-beta